AMR is recognized as one of the most serious public health concerns worldwide. The WHO, G7, G20, and many world leaders have acknowledged the growing dangers AMR presents, and the threat it poses to achieving the Sustainable Development Goals (SDGs).

In 2016, the United Nations called for action from governments and various sectors to comprehensively address the implications of AMR and implement strategies at national level. The AMR Industry Alliance is the life-sciences industry’s response.

IFPMA was instrumental in establishing the AMR Industry Alliance in 2017 and remains its legal secretariat.

Today, the Alliance brings together over 100 biotech, diagnostics, generics, and research-based pharmaceutical companies and associations to collaborate, provide solutions, and report on progress.

The principles of the AMR Industry Alliance are based on its two founding documents: the Davos Declaration and the Industry Roadmap. Since then, Alliance commitments have evolved in line with industry progress and global priorities.

Looking ahead, continued cross-sector collaborations, along with policy and regulatory changes toward a more sustainable marketplace, are much needed.

Four key focus areas

Research and science

Invest in R&D to meet public health needs with new innovative diagnostics and treatments

Appropriate use

Work to reduce the development of AMR


Improve access to high-quality antibiotics and make sure new ones are available to everyone


Reduce the environmental impact of manufacturing


members from R&D-based companies, diagnostics, generics, biotechnology, and trade associations


invested annually in AMR-related R&D by Alliance members in FY 2019 and 2020


progress reports published since the Alliance was launched

Measuring progress: The Alliance Progress Report

To drive and measure industry progress against AMR, the Alliance regularly publishes a Progress Report.

The Report reflects collective achievements from the life sciences industry to minimize the spread of AMR.

It reports results from across Alliance membership on their current AMR activities related to research and science, access, appropriate use, and manufacturing & environment.

2021 Progress report

The leading coalition of biotechnology, diagnostics, generic, and large research-based pharmaceutical companies continues to demonstrate focus and leadership from the life sciences sector.

Antibiotic Manufacturing Standard

In June 2022, the AMR Industry Alliance launched its Antibiotic Manufacturing Standard, facilitated by BSI Standards Limited (BSI).

The Standard builds on years of the Alliance’s leading work on responsible antibiotic manufacture, providing clear guidance to manufacturers in the global antibiotic supply chain to make sure their antibiotics are made responsibly.

It formalizes the Alliance’s 2018 Common Antibiotic Manufacturing Framework, which described a risk-based approach to assessing and controlling antibiotic manufacturing waste streams.

AMR Industry Alliance members have made notable contributions to tackling the urgency of the AMR challenge on multiple fronts.

Sonja Marjanovic

Director, Healthcare Innovation, Industry, and Policy, RAND Europe

I have been particularly heartened to see the work undertaken to tackle the manufacturing– environment pathway for antibiotics. As part of this work, the Alliance developed a common framework for responsible antibiotic manufacturing.

Professor Dame Sally Davies

UK Special Envoy on Antimicrobial Resistance (AMR)

…governments, industry, and other stakeholders must work together...I look to the AMR Industry Alliance to play its part at the forefront of these efforts.

Professor Dame Sally Davies

UK Special Envoy on Antimicrobial Resistance (AMR)

The Alliance in action

The AMR Industry Alliance is actively investing in research to develop new antibiotics and vaccines. Find out more about our work and how you can get involved.